Recent Updates
Recently added Catalysts

Hospitalists Results Manager

Phase 3

Healthy | Unknown | Other |Harvard Bioscience, Inc.|Last Updated: Mar 2, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00146354The Effects of a Results Management System on Physician Awareness of Post-Discharge Test ResultsPHASE3 COMPLETED - - -Mar 2, 20072 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeECT
Interventions
NameTypeDescription
Hospitalists Results ManagerBEHAVIORAL -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Admitted under enrolled study Attendings at the two study locations * Patient had test result finalized after discharge and prior to subsequent admission Exclusion Criteria: * Test result noted in discharge summary * Test result not clinically actionable

Countries:United States
Unlock Eligibility Criteria